Table 1 General characteristics of patients

From: Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis

 

M-HLH

HM

N

20

17

Gender (M/F)

12/8

14/3

Age (year)

7.09 ± 5.38

9.03 ± 3.83

weight (kg)

24.63 ± 15.32

30.66 ± 14.04

Primary Disease

 ALL

9

12

 AML

1

2

 Lymphoma

4

2

 PTLD

6

0

 ITP

0

1

*Sepsis

15/20 (75%)

5/17 (29.4%)

Bacteria

11/15 (73.3%)

4/5 (80%)

Viruses

7/15 (46.7%)

2/5 (40%)

Fungi

1/15 (6.7%)

1/5 (20%)

Cell activation files

*CD38 + HLA-DR + CD8 + T cells % median (IQR)

58.39 (42.7–70.0)

19.74 (9.6–30.4)

*INFγ median (IQR) (pg/ml)

77.32 (51.6–355)

2.44 (2.44–5.4)

CD14 + HLA-DR+monocytes%

92.53 (83.07–98.11)

90.63 (44.75–96.03)

LDH median (IQR) (U/L)

452 (249–1252)

301 (141–807)

*Ferritin median (IQR) (ng/ml)

2757 (897–5381)

941 (354–2670)

sIL-2R median (IQR) (U/ml)

2777 (2500–7500)

2260 (1161–3950)

*pSOFA median (IQR)

12 (7.5–14)

8 (4–10)

PRISM III median (IQR)

15 (9–17.8)

12 (8.5–17)

Corticosteroid Use

20/20 100%

13/17 76.5%

 High dose

40%

0%

 Low dose

60%

100%

 None

0

23.6%

Death

7/20 (35%)

2/17 (12%)

  1. ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, ITP idiopathic thrombocytopenic purpura, PTLD Post-transplant lymphoproliferative disorders, *represent p < 0.05.
Back to article page